Drugs / PF-00572778
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00580190 | Sep 2007 → Feb 2008 | — | Pfizer | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-00572778 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00580190 ↗ |
| Action | Inhibit | “PF-00572778, a CRH antagonist, is expected to attenuate adrenocorticotropin (ACTH) and cortisol responses to naloxone by blocking the effect of the CRH increases induced by...” NCT00580190 ↗ |